Cellectis 放弃异体 CAR-T、转向临床前体内基因编辑，股价盘中暴跌约41%

Cellectis quits CAR-Ts and pivots to ‘in vivo’ gene editing | BioPharma Dive
Skip to main content
CONTINUE TO SITE ➞
Don't miss tomorrow's biopharma industry news
Let BioPharma Dive's free newsletter keep you informed, straight from your inbox.
Daily Dive
M-F
Commercialization Weekly
Every Wednesday
Gene Therapy Weekly
Every Thursday
Emerging Biotech Weekly
Every Tuesday
By signing up to receive our newsletter, you agree to our
Terms of Use
and
Privacy Policy
. You can unsubscribe at anytime.
Informa TechTarget
|
Healthcare Dive
MedTech Dive
PharmaVoice
Xtelligent Pharma Life Sciences
Explore our brands
An Informa TechTarget Publication
Search
People also ask
Loading questions...
An article from
Dive Brief
Cellectis quits CAR-Ts and pivots to ‘in vivo’ gene editing
Long a frontrunner in donor-derived cell therapy research, the French biotech cited a shifting landscape in changing course and choosing to offload its lead programs.
Published Sept. 14, 2026
Jonathan Gardner
Senior Reporter
Share
Copy link
Email
LinkedIn
X/Twitter
Facebook
Print
License
Add us on Google
Cellectis will focus resources going forward on "in vivo" gene editing medicines for cardiovascular disease, the company said on Sept. 14, 2026.
Getty Images
Dive Brief:
Cellectis is
giving up on donor-derived cell therapies
and shifting its focus to gene editing medicines, stating in a Monday announcement that the “commercial and clinical landscape” for combatting blood cancers with so-called CAR-T treatments has “changed materially.”
The decision dramatically lengthens Cellectis’ road to a marketed medicine, as the company is ending work on treatments that were in clinical development and turning to therapies that haven’t been tested in humans. One CAR-T program it discovered and out-licensed has advanced as far as Phase 2 testing.
Cellectis claimed that its new strategy represents the “most effective use of its financial and operational resources.” Investors expressed disappointment, however, as company shares fell as much as 43% in morning trading and, at around $2 apiece, trade just above all-time lows.
Dive Insight:
Founded around the turn of the century with gene editing technology developed by Institut Pasteur, Cellectis has long been a frontrunner in advancing “allogeneic” therapies built from the cells of donors. It raised $228 million in an
initial public offering
in 2015 and, since then, has worked to prove its treatments could become a simpler alternative to the complicated, personalized CAR-T therapies now available for multiple blood cancers.
Yet like many of its peers, Cellectis has struggled. Individualized, “autologous” cell therapies have set a high bar for winning approvals in malignancies like leukemia, lymphoma and multiple myeloma. Their allogeneic counterparts have had difficulty matching those results, leading many developers in recent years to
shift resources to other areas
, such as autoimmune disease research.
As recently as early August, Cellectis
was touting data
for two clinical-stage cell therapies called lasme-cel and eti-cel in leukemia and lymphoma. But treatment protocols in many blood cancers have changed drastically as new types of medicines — from cell therapies to bispecific antibodies and more — have been approved. Those developments have heightened Cellectis’ competition, reduced the addressable patient populations for each therapy and slowed study enrollment. “We believe these trends are likely to continue and further constrain the commercial opportunity for both product candidates,” the company said in a statement.
Cellectis will seek “strategic partnering opportunities” to maximize the value of lasme-cel and eti-cel. The company will also “realign its organization” and support existing partnerships with Allogene, Servier, AstraZeneca and Iovance Biotherapeutics, the company said.
The new drugs it’ll work on, meanwhile, are prospective cardiovascular disease treatments that are still in preclinical development. One, called HEAL-101, uses base editing technology to target a gene, APOC3, linked to high triglycerides. Another known as HEAL-201 harnesses an epigenetic editing approach to lower levels of the cholesterol-regulating protein PCSK9. Cellectis will face an uphill battle in both cases, as multiple medications aimed at APOC3 and PCSK9 are already available.
Cellectis’ strategic shift comes in the wake of
multiple recent high-profile failures
in
cardiovascular disease studies
. The latest setback happened just over a week ago, when a therapy from
Novartis
and Ionis Pharmaceuticals fell short in a major study that had widely been expected to succeed.
Add us on Google
Share
Copy link
Email
LinkedIn
X/Twitter
Facebook
Print
License
Filed Under:
Gene Therapy
BioPharma Dive news delivered to your inbox
Get the free daily newsletter read by industry experts
Email:
Select Newsletter:
Daily Dive
M-F
Select Newsletter:
Commercialization Weekly
Every Wednesday
Select Newsletter:
Gene Therapy Weekly
Every Thursday
Select Newsletter:
Emerging Biotech Weekly
Every Tuesday
Select user consent:
By signing up to receive our newsletter, you agree to our
Terms of Use
and
Privacy Policy
. You can unsubscribe at anytime.
Sign up
A valid email address is required.
Please select at least one newsletter.
Editors' picks
Kevin Frayer via Getty Images
China competition
Drugs from China are reshaping biotech. Track the licensing deals here.
Including a new deal with Roche last week, Simcere Pharmaceutical has now inked five cross-border licensing pacts since the start of 2025 that are collectively worth up to $5.66 billion.
By Ben Fidler •
Updated Sept. 2, 2026
Permission granted by Daiichi Sankyo
ASCO25
Daiichi Sankyo struck gold with ‘ADC’ cancer drugs. Its new CEO has to figure out what’s next.
Enhertu, Datroway and other antibody-drug conjugates developed by Daiichi Sankyo have made the company a leader in a competitive field. Hiroyuki Okuzawa is working to keep it that way.
By Ned Pagliarulo •
June 4, 2025
BioPharma Dive news delivered to your inbox
Get the free daily newsletter read by industry experts
Email:
Select Newsletter:
Daily Dive
M-F
Select Newsletter:
Commercialization Weekly
Every Wednesday
Select Newsletter:
Gene Therapy Weekly
Every Thursday
Select Newsletter:
Emerging Biotech Weekly
Every Tuesday
Select user consent:
By signing up to receive our newsletter, you agree to our
Terms of Use
and
Privacy Policy
. You can unsubscribe at anytime.
Sign up
A valid email address is required.
Please select at least one newsletter.
Company Announcements
View all
|
Post a press release
FDA Approves Tablet Form of Zanubrutinib for All Approved Indications
From BeOne Medicines
September 09, 2026
NeuroGT Announces FDA Clearance of Investigational New Drug Application for NGT-104, an AAV9 G…
From NeuroGT
September 03, 2026
ACTO Achieves Veeva Gold Product Partner Status, Following a Nearly Decade-Long Collaboration …
From ACTO
September 02, 2026
Bioforum The Data Masters Expands Global Footprint with New Office and Global Capability Cente…
From Bioforum The Data Masters
August 25, 2026
Editors' picks
Kevin Frayer via Getty Images
China competition
Drugs from China are reshaping biotech. Track the licensing deals here.
Including a new deal with Roche last week, Simcere Pharmaceutical has now inked five cross-border licensing pacts since the start of 2025 that are collectively worth up to $5.66 billion.
By Ben Fidler •
Updated Sept. 2, 2026
Permission granted by Daiichi Sankyo
ASCO25
Daiichi Sankyo struck gold with ‘ADC’ cancer drugs. Its new CEO has to figure out what’s next.
Enhertu, Datroway and other antibody-drug conjugates developed by Daiichi Sankyo have made the company a leader in a competitive field. Hiroyuki Okuzawa is working to keep it that way.
By Ned Pagliarulo •
June 4, 2025
Latest in Gene Therapy
mRNA cancer vaccines’ biggest barriers to market
By Alexandra Pecci
BrainChild hauls in $116M to make cell therapies for childhood brain cancers
By Gwendolyn Wu
The hidden scale-out problem behind CAR-T’s growth
By Sy Mukherjee
Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts
By Jonathan Gardner
This website is owned and operated by
Informa TechTarget
,
a global network that informs, influences and connects the world's technology buyers and sellers.
© 2025 TechTarget, Inc. or its subsidiaries. All rights reserved. An Informa PLC company.
Privacy policy
|
Terms of use
|
Take down policy
|
Cookie Preferences / Do Not Sell